ZOMETA® Case Study | Renal Cell Carcinoma: Reasons For ZOMETA

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Renal Cell Carcinoma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETAŽ Renal Cell Carcinoma Patient Case Study Carlo

Carlo V.

Aged 67 years
Retired accountant
Takes sculpting classes twice a week

Page

1 2 3

As new treatments extend survival, the threat of an SRE increases
for patients like Carlo

Median progression-free survival (PFS) is 11.8 months for patients with advanced renal cell carcinoma treated with sunitinib (median survival not yet reported)⁴
Without treatment, the time to first SRE is less than 2.5 months for patients with advanced renal cell carcinoma²

Time to first SRE vs PFS in advanced
renal cell carinoma^2,4

ZOMETA®: Median time to first SRE vs. Survival time in renal cell carcinoma patients

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

As new treatments extend survival, the threat of an SRE increasesfor patients like Carlo

As new treatments extend survival, the threat of an SRE increases
for patients like Carlo